Combined mRNA microarray and proteomic analysis of eutopic endometrium of women with and without endometriosis

A Fassbender, Amelie Fassbender, N Verbeeck, Nico Verbeeck, Daniela Börnigen, D Börnigen, C M Kyama, Cleophas Kyama, Attila Bokor, A Bokor, Alexandra Vodolazkaia, A Vodolazkaia, Karen Peeraer, K Peeraer, Carla Tomassetti, C Tomassetti, C Meuleman, Christel Meuleman, Olivier Gevaert, O Gevaert, R Van de Plas, Raf Van de Plas, Fabian Ojeda, F Ojeda, B De Moor, Bart De Moor, Yves Moreau, Y Moreau, Etienne Waelkens, E Waelkens, Thomas D'Hooghe, Thomas D’Hooghe, T M D'Hooghe
Human Reproduction · 2012 · vol. 27(7) , pp. 2020–2029 · doi:10.1093/humrep/des127 · PMID:22556377 · W2165696199
article OA: bronze CC0 ⤵ 84 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

Proteomic analysis of luteal phase endometrium identified five peptide peaks diagnostic for endometriosis with high sensitivity and specificity, while mRNA analysis showed no differential gene expression between endometriosis patients and controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: An early semi-invasive diagnosis of endometriosis has the potential to allow early treatment and minimize disease progression but no such test is available at present. Our aim was to perform a combined mRNA microarray and proteomic analysis on the same eutopic endometrium sample obtained from patients with and without endometriosis. METHODS: mRNA and protein fractions were extracted from 49 endometrial biopsies obtained from women with laparoscopically proven presence (n= 31) or absence (n= 18) of endometriosis during the early luteal (n= 27) or menstrual phase (n= 22) and analyzed using microarray and proteomic surface enhanced laser desorption ionization-time of flight mass spectrometry, respectively. Proteomic data were analyzed using a least squares-support vector machines (LS-SVM) model built on 70% (training set) and 30% of the samples (test set). RESULTS: mRNA analysis of eutopic endometrium did not show any differentially expressed genes in women with endometriosis when compared with controls, regardless of endometriosis stage or cycle phase. mRNA was differentially expressed (P< 0.05) in women with (925 genes) and without endometriosis (1087 genes) during the menstrual phase when compared with the early luteal phase. Proteomic analysis based on five peptide peaks [2072 mass/charge (m/z); 2973 m/z; 3623 m/z; 3680 m/z and 21133 m/z] using an LS-SVM model applied on the luteal phase endometrium training set allowed the diagnosis of endometriosis (sensitivity, 91; 95% confidence interval (CI): 74-98; specificity, 80; 95% CI: 66-97 and positive predictive value, 87.9%; negative predictive value, 84.8%) in the test set. CONCLUSION: mRNA expression of eutopic endometrium was comparable in women with and without endometriosis but different in menstrual endometrium when compared with luteal endometrium in women with endometriosis. Proteomic analysis of luteal phase endometrium allowed the diagnosis of endometriosis with high sensitivity and specificity in training and test sets. A potential limitation of our study is the fact that our control group included women with a normal pelvis as well as women with concurrent pelvic disease (e.g. fibroids, benign ovarian cysts, hydrosalpinges), which may have contributed to the comparable mRNA expression profile in the eutopic endometrium of women with endometriosis and controls.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Oligonucleotide Array Sequence Analysis Proteomics RNA, Messenger Adult Biomarkers Biomarkers Biomarkers, Tumor Biomarkers, Tumor Biopsy Case-Control Studies Endometriosis Endometriosis Endometrium Endometrium Female Humans Oligonucleotide Array Sequence Analysis Peptides

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:17.081435+00:00
License: CC0 · commercial use OK